Production of dendritic cell vaccines using different methods with equivalent results: Implications for emerging centers

Duarte, Adriana da Silva Santos; Zangirolami, Audrey Basso; Niemann, Fernanda Soares; Honma, Helen Naemi; Amaro, Emerson Clayton; Perroud, Maurício W.; Pericole, Fernando V; Gilli, Simone Cristina Olenscki; Benites, Bruno Deltreggia; Saad, Sara Teresinha Olalla

doi:10.1016/j.htct.2022.11.006

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in vitro expansion of DCs is more complex and costly, and the number of DCs required for vaccine production is large. To combat these issues, researchers have proposed the use of cell enrichment methods, sorting of fluorescently labeled cells, differentiation, and isolation from monocytes or leukocytes to improve the generation of isolated DCs [13]. Neoantigens can be transfected, pulsed, or electroporated onto DCs [14][15][16].…”

Section: Dendritic Cell Vaccinesmentioning

confidence: 99%

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment

Huang,

Zhu,

Yang

et al. 2024

Molecules

View full text Add to dashboard Cite

Tumor vaccines have been considered a promising therapeutic approach for treating cancer in recent years. With the development of sequencing technologies, tumor vaccines based on neoantigens or genomes specifically expressed in tumor cells, mainly in the form of peptides, nucleic acids, and dendritic cells, are beginning to receive widespread attention. Therefore, in this review, we have introduced different forms of neoantigen vaccines and discussed the development of these vaccines in treating cancer. Furthermore, neoantigen vaccines are influenced by factors such as antigen stability, weak immunogenicity, and biosafety in addition to sequencing technology. Hence, the biological nanomaterials, polymeric nanomaterials, inorganic nanomaterials, etc., used as vaccine carriers are principally summarized here, which may contribute to the design of neoantigen vaccines for improved stability and better efficacy.

show abstract

Section: Dendritic Cell Vaccinesmentioning

confidence: 99%

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment

Huang,

Zhu,

Yang

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…Широко изучены и применяются ДК, выделенные из моноцитов [43]. В оригинальной статье бразильских исследователей проводили сравнительный анализ выхода ДК, полученных из моноцитов автоматическим и ручным методом с использованием наслаивания на градиенте плотности [44].…”

Section: моновакцины на основе дендритных клетокunclassified

Perspectives for antitumor vaccines application

Nikolaeva,

Golderova,

Egorov

et al. 2022

Russian Journal of Oncology

View full text Add to dashboard Cite

One of the promising areas in immunotherapy are tumour-specific vaccines based on immunocompromised cells. DC-based personalized neoantigenic cellular vaccines have promising antitumor effects in clinical practice. Dendritic cell-based vaccines have a number of advantages, one example being the ability to engage both innate and adaptive immunity, as well as to develop long-term immunological memory against tumor recurrence. DCs are the most professional and consistent antigens and are more effective in activating resting T cells. The review provides the most up-to-date information on cancer vaccines, as well as an analysis of the types of cancer vaccines from domestic and foreign sources. The conclusion of this brief review is the wide variety of types of tumor-specific vaccines and their rapid improvement.

show abstract

Production of dendritic cell vaccines using different methods with equivalent results: Implications for emerging centers

Cited by 2 publications

References 20 publications

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment

Perspectives for antitumor vaccines application

Contact Info

Product

Resources

About